Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

INTRODUCTION: This phase I study evaluated nivolumab combined with erlotinib in patients with advanced EGFR-mutant NSCLC. METHODS: Patients with advanced EGFR-mutant NSCLC who were EGFR tyrosine kinase inhibitor (TKI)-naive or TKI-treated but had not received chemotherapy were treated with nivolumab 3 mg/kg every 2 weeks and erlotinib 150 mg/d until disease progression or unacceptable toxicity. The primary objective was safety and tolerability.